Scarica l'app Stockscreener
2.755
0.54%
-0.015
Precedente Chiudi:
$2.77
Aprire:
$2.79
Volume 24 ore:
498.15K
Relative Volume:
0.17
Capitalizzazione di mercato:
$476.72M
Reddito:
$7.25M
Utile/perdita netta:
$-17.41M
Rapporto P/E:
-10.49
EPS:
-0.2627
Flusso di cassa netto:
$-38.33M
1 W Prestazione:
+5.96%
1M Prestazione:
+27.55%
6M Prestazione:
+98.20%
1 anno Prestazione:
+774.05%
Intervallo 1D:
$2.72
$2.81
Intervallo di 1 settimana:
$2.58
$2.81
Portata 52W:
$0.2701
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.755 | 467.20M | 7.25M | -17.41M | -38.33M | -0.2627 |
VRTX
Vertex Pharmaceuticals Inc
|
424.50 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
703.74 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
787.34 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.31 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.39 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Roth Capital | Buy |
| 2025-11-17 | Iniziato | Leerink Partners | Outperform |
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Ovid Therapeutics (NASDAQ: OVID) outlines 2026 virtual meeting, pay and audit votes - Stock Titan
SEC Form DEFA14A filed by Ovid Therapeutics Inc. - Quantisnow
[ARS] Ovid Therapeutics Inc. SEC Filing - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) registers 29.9M resale shares from private placement - Stock Titan
[EFFECT] Ovid Therapeutics Inc. SEC Filing - Stock Titan
OVID Ovid Therapeutics Inc. far exceeds Q4 2025 EPS expectations, shares rise nearly four percent.Profit Guidance - Cổng thông tin điện tử Tỉnh Sơn La
OVID (Ovid Therapeutics) delivers blowout Q4 2025 results, but stock dips slightly amid mild investor profit taking.Deceleration Risk - Xã Thanh Hà
29.86M-share resale registration by Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy By Investing.com - Investing.com India
Ovid Therapeutics receives $53.9 million from warrant exercises By Investing.com - Investing.com India
Ovid Therapeutics Boosts Capital Through Warrant Exercises - TipRanks
Ovid Therapeutics receives $53.9 million from warrant exercises - Investing.com
Ovid Therapeutics sees $53.9M gross proceeds as Series A warrants mostly exercised - TradingView
Warrant exercises bring Ovid Therapeutics (NASDAQ: OVID) $53.9M cash - Stock Titan
H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy - Investing.com
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts - MarketBeat
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Announces Target Price $5.24 - 富途牛牛
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - 富途牛牛
OVID.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
OVID Reiterated by Wedbush -- Price Target Maintained at $7.00 - GuruFocus
Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential By Investing.com - Investing.com South Africa
Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential - Investing.com
Ovid Therapeutics' (OVID) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS DisordersSlideshow - Seeking Alpha
Value Recap: What hedge funds are buying Ovid Therapeutics Inc2026 Analyst Calls & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Short Interest in Ovid Therapeutics (NASDAQ:OVID) Increases By 71.2% - MarketBeat
VIX Spike: Does Ovid Therapeutics Inc have declining or rising EPS2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
HC Wainwright Issues Positive Forecast for OVID Earnings - MarketBeat
Whale Trades: What are Ovid Therapeutics Incs growth levers2026 Gainers & Low Volatility Stock Recommendations - baoquankhu1.vn
OVID Should I Buy - Intellectia AI
H.C. Wainwright raises Ovid Therapeutics stock price target to $4 By Investing.com - Investing.com Australia
[Form 4] Ovid Therapeutics Inc. Insider Trading Activity - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) director granted RSUs in lieu of cash pay - Stock Titan
Director Kevin Fitzgerald awarded Ovid Therapeutics (OVID) RSU compensation - Stock Titan
Trade Recap: Why is Ovid Therapeutics Inc stock going up2026 Top Gainers & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Ovid Therapeutics Surge: Positive Phase 1 Data Ignites Market Confidence - timothysykes.com
Ovid Therapeutics (OVID): HC Wainwright & Co. Raises Price Targe - GuruFocus
H.C. Wainwright raises Ovid Therapeutics stock price target to $4 - Investing.com
Big Money Moves: Why is Ovid Therapeutics Inc stock going up - baoquankhu1.vn
Ovid Therapeutics Inc. (OVID) stock price, news, quote and history - Yahoo Finance UK
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - The Manila Times
Ovid Therapeutics Shares Surge After Positive Phase 1 Results and Financing News - StocksToTrade
Earnings Report: Is Ovid Therapeutics Inc being accumulated by smart money2026 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Is Ovid Therapeutics (OVID) Stock Trending Up | Price at $2.31, Up 4.77%Open Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Ovid Therapeutics Inc (OVID) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
OVID.O Technical Analysis & Stock Price Forecast - Intellectia AI
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ovid Therapeutics Inc Azioni (OVID) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
2.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):